结直肠癌的临床病理学,分子和预后特征具有KRAS c.34G>T (p.G12C) 突变
Satoko Ugai1,2, Qian Yao1, Yasutoshi Takashima1,3
1Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA.
KRAS p.G12C突变定义了一个独特的结直肠癌亚型,具有独特的分子和临床特征. 这些瘤表现出改变的甲基化模式,并与增加的死亡率有关,这表明向治疗可能是有益的.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 克拉斯p.G12C突变是先进结直肠癌治疗的新兴目标.
- 克拉斯p.G12C突变结直肠癌的独特生物学和临床特征尚未完全阐明.
研究的目的:
- 调查假设KRAS c.34G>T (p.G12C) 突变结直肠癌代表了一个独特的瘤亚型.
- 描述KRAS c.34G>T (p.G12C) 突变结直肠瘤的临床和分子特征.
主要方法:
- 利用了1347种结肠直肠癌的前性队列事件瘤生物库.
- 使用分子分析检测到KRAS c.34G>T (p.G12C) 突变和其他KRAS突变.
- 分析了CpG岛甲基剂表型 (CIMP) 状态,微卫星不稳定性 (MSI),BRAF,PIK3CA突变和LINE-1甲基化.
- 评估与KRAS突变状态相关的瘤特异性死亡率.
主要成果:
- 在3.2%的病例中发现了KRAS c.34G>T (p.G12C) 突变.
- 与KRAS野生型瘤相比,KRAS c.34G>T突变患者的CIMP低和CIMP高发病率较高.
- 这些瘤与部位置,非微卫星不稳定性-高状态,BRAF野生类型,PIK3CA突变和LINE-1低甲基化有关.
- 与KRAS野生型瘤相比,KRAS c.34G>T突变瘤显示结直肠癌特异性死亡率 (1.82) 的危险比率显著增加.
结论:
- KRAS c.34G>T (p.G12C) 突变结直肠癌是一种独特的亚型,具有独特的分子和临床特征.
- 这些发现支持在这种患者群体中针对性治疗的潜力,例如KRAS抑制剂.
- 这种亚型与预后较差有关,突出显示需要进一步研究和量身定制的治疗策略.
更多相关视频
07:08Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein
Published on: January 16, 2020
11:20Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology
Published on: March 21, 2018
相关概念视频
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
The Ras Gene
Ras is a...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
